Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis
The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AId-B and AID-BR models) in 22...
Gespeichert in:
Veröffentlicht in: | Journal of the American College of Cardiology 1987-06, Vol.9 (6), p.1349-1356 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1356 |
---|---|
container_issue | 6 |
container_start_page | 1349 |
container_title | Journal of the American College of Cardiology |
container_volume | 9 |
creator | Gabry, Mark D. Brodman, Richard Johnston, Debra Frame, Rosemary Kim, Soo G. Waspe, Lawrence E. Fisher, John D. Furman, Seymour |
description | The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AId-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of congestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50%) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41%) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1% in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8%.
The cumulative device survival of the 36 AID-B units was 92 ± 5.62% at 15 months but diminished to 37 ± 14.4% by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator.
The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system. |
doi_str_mv | 10.1016/S0735-1097(87)80477-1 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77543450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735109787804771</els_id><sourcerecordid>77543450</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-70ceb85972d4abfeb04b4b4bad07c9e13157e0d047ace68e06a702142f8fe9a13</originalsourceid><addsrcrecordid>eNqFkFFrFDEQx4Mo9ax-hEIeRBTcmmw2l2xfpBSthYKC-hxmk1mNZnevSXbhvr1Z77jXkkAe5peZ-f8IueDskjO-_fCdKSErzlr1Vqt3mjVKVfwJ2XApdSVkq56SzQl5Tl6k9IcxttW8PSNnQupG1WJDHq7nPA2QvaV-2AUYM3QBqYXo_LRgzBgrh73vog8B8hSv6LdC45hpmuPiFwjvaQe5cHsapvEXLj7vKYyOpt-T_UsdBr-sRRgh7JNPL8mzHkLCV8f3nPz8_OnHzZfq_uvt3c31fWWbWuRKMYudLjFq10DXY8eabj3gmLItcsGlQuZKbLC41ci2oFjNm7rXPbbAxTl5c-i7i9PDjCmbwSeLJcWI05yMUrIRjWQFlAfQximliL3ZRT9A3BvOzKra_FdtVo9Gl7uqNuuAi-OAuRvQnX4d3Zb662MdkoXQRxitTydM10JKvrb5eMCwyFg8RpNs8WvR-Yg2Gzf5Rxb5B86Engw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77543450</pqid></control><display><type>article</type><title>Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Gabry, Mark D. ; Brodman, Richard ; Johnston, Debra ; Frame, Rosemary ; Kim, Soo G. ; Waspe, Lawrence E. ; Fisher, John D. ; Furman, Seymour</creator><creatorcontrib>Gabry, Mark D. ; Brodman, Richard ; Johnston, Debra ; Frame, Rosemary ; Kim, Soo G. ; Waspe, Lawrence E. ; Fisher, John D. ; Furman, Seymour</creatorcontrib><description>The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AId-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of congestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50%) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41%) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1% in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8%.
The cumulative device survival of the 36 AID-B units was 92 ± 5.62% at 15 months but diminished to 37 ± 14.4% by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator.
The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/S0735-1097(87)80477-1</identifier><identifier>PMID: 3584723</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Electric Countershock - adverse effects ; Electric Countershock - instrumentation ; Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care ; Equipment Design ; Equipment Failure ; Female ; Humans ; Intensive care medicine ; Male ; Medical sciences ; Middle Aged ; Postoperative Complications ; Prostheses and Implants ; Tachycardia - mortality ; Tachycardia - therapy</subject><ispartof>Journal of the American College of Cardiology, 1987-06, Vol.9 (6), p.1349-1356</ispartof><rights>1987 American College of Cardiology Foundation</rights><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-70ceb85972d4abfeb04b4b4bad07c9e13157e0d047ace68e06a702142f8fe9a13</citedby><cites>FETCH-LOGICAL-c423t-70ceb85972d4abfeb04b4b4bad07c9e13157e0d047ace68e06a702142f8fe9a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0735109787804771$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8235511$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3584723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gabry, Mark D.</creatorcontrib><creatorcontrib>Brodman, Richard</creatorcontrib><creatorcontrib>Johnston, Debra</creatorcontrib><creatorcontrib>Frame, Rosemary</creatorcontrib><creatorcontrib>Kim, Soo G.</creatorcontrib><creatorcontrib>Waspe, Lawrence E.</creatorcontrib><creatorcontrib>Fisher, John D.</creatorcontrib><creatorcontrib>Furman, Seymour</creatorcontrib><title>Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AId-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of congestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50%) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41%) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1% in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8%.
The cumulative device survival of the 36 AID-B units was 92 ± 5.62% at 15 months but diminished to 37 ± 14.4% by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator.
The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system.</description><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Electric Countershock - adverse effects</subject><subject>Electric Countershock - instrumentation</subject><subject>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</subject><subject>Equipment Design</subject><subject>Equipment Failure</subject><subject>Female</subject><subject>Humans</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Postoperative Complications</subject><subject>Prostheses and Implants</subject><subject>Tachycardia - mortality</subject><subject>Tachycardia - therapy</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkFFrFDEQx4Mo9ax-hEIeRBTcmmw2l2xfpBSthYKC-hxmk1mNZnevSXbhvr1Z77jXkkAe5peZ-f8IueDskjO-_fCdKSErzlr1Vqt3mjVKVfwJ2XApdSVkq56SzQl5Tl6k9IcxttW8PSNnQupG1WJDHq7nPA2QvaV-2AUYM3QBqYXo_LRgzBgrh73vog8B8hSv6LdC45hpmuPiFwjvaQe5cHsapvEXLj7vKYyOpt-T_UsdBr-sRRgh7JNPL8mzHkLCV8f3nPz8_OnHzZfq_uvt3c31fWWbWuRKMYudLjFq10DXY8eabj3gmLItcsGlQuZKbLC41ci2oFjNm7rXPbbAxTl5c-i7i9PDjCmbwSeLJcWI05yMUrIRjWQFlAfQximliL3ZRT9A3BvOzKra_FdtVo9Gl7uqNuuAi-OAuRvQnX4d3Zb662MdkoXQRxitTydM10JKvrb5eMCwyFg8RpNs8WvR-Yg2Gzf5Rxb5B86Engw</recordid><startdate>19870601</startdate><enddate>19870601</enddate><creator>Gabry, Mark D.</creator><creator>Brodman, Richard</creator><creator>Johnston, Debra</creator><creator>Frame, Rosemary</creator><creator>Kim, Soo G.</creator><creator>Waspe, Lawrence E.</creator><creator>Fisher, John D.</creator><creator>Furman, Seymour</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19870601</creationdate><title>Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis</title><author>Gabry, Mark D. ; Brodman, Richard ; Johnston, Debra ; Frame, Rosemary ; Kim, Soo G. ; Waspe, Lawrence E. ; Fisher, John D. ; Furman, Seymour</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-70ceb85972d4abfeb04b4b4bad07c9e13157e0d047ace68e06a702142f8fe9a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Electric Countershock - adverse effects</topic><topic>Electric Countershock - instrumentation</topic><topic>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</topic><topic>Equipment Design</topic><topic>Equipment Failure</topic><topic>Female</topic><topic>Humans</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Postoperative Complications</topic><topic>Prostheses and Implants</topic><topic>Tachycardia - mortality</topic><topic>Tachycardia - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gabry, Mark D.</creatorcontrib><creatorcontrib>Brodman, Richard</creatorcontrib><creatorcontrib>Johnston, Debra</creatorcontrib><creatorcontrib>Frame, Rosemary</creatorcontrib><creatorcontrib>Kim, Soo G.</creatorcontrib><creatorcontrib>Waspe, Lawrence E.</creatorcontrib><creatorcontrib>Fisher, John D.</creatorcontrib><creatorcontrib>Furman, Seymour</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gabry, Mark D.</au><au>Brodman, Richard</au><au>Johnston, Debra</au><au>Frame, Rosemary</au><au>Kim, Soo G.</au><au>Waspe, Lawrence E.</au><au>Fisher, John D.</au><au>Furman, Seymour</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>1987-06-01</date><risdate>1987</risdate><volume>9</volume><issue>6</issue><spage>1349</spage><epage>1356</epage><pages>1349-1356</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><abstract>The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AId-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of congestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50%) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41%) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1% in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8%.
The cumulative device survival of the 36 AID-B units was 92 ± 5.62% at 15 months but diminished to 37 ± 14.4% by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator.
The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>3584723</pmid><doi>10.1016/S0735-1097(87)80477-1</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0735-1097 |
ispartof | Journal of the American College of Cardiology, 1987-06, Vol.9 (6), p.1349-1356 |
issn | 0735-1097 1558-3597 |
language | eng |
recordid | cdi_proquest_miscellaneous_77543450 |
source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Electric Countershock - adverse effects Electric Countershock - instrumentation Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care Equipment Design Equipment Failure Female Humans Intensive care medicine Male Medical sciences Middle Aged Postoperative Complications Prostheses and Implants Tachycardia - mortality Tachycardia - therapy |
title | Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T02%3A21%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Automatic%20implantable%20cardioverter-defibrillator:%20Patient%20survival,%20battery%20longevity%20and%20shock%20delivery%20analysis&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Gabry,%20Mark%20D.&rft.date=1987-06-01&rft.volume=9&rft.issue=6&rft.spage=1349&rft.epage=1356&rft.pages=1349-1356&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/S0735-1097(87)80477-1&rft_dat=%3Cproquest_cross%3E77543450%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77543450&rft_id=info:pmid/3584723&rft_els_id=S0735109787804771&rfr_iscdi=true |